Fmr LLC Has $1.41 Million Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

FMR LLC lowered its position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 62.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,024,583 shares of the company's stock after selling 1,708,879 shares during the quarter. FMR LLC owned approximately 0.37% of Lyell Immunopharma worth $1,414,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its position in Lyell Immunopharma by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company's stock worth $68,000 after purchasing an additional 19,287 shares during the period. SG Americas Securities LLC boosted its stake in shares of Lyell Immunopharma by 78.1% in the 3rd quarter. SG Americas Securities LLC now owns 57,566 shares of the company's stock valued at $79,000 after purchasing an additional 25,247 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Lyell Immunopharma by 197.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company's stock worth $58,000 after buying an additional 26,635 shares during the period. Exchange Traded Concepts LLC raised its stake in shares of Lyell Immunopharma by 37.3% during the third quarter. Exchange Traded Concepts LLC now owns 135,050 shares of the company's stock worth $186,000 after buying an additional 36,715 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in Lyell Immunopharma in the third quarter valued at approximately $52,000. Institutional investors and hedge funds own 66.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on LYEL shares. HC Wainwright reaffirmed a "neutral" rating and set a $1.00 target price on shares of Lyell Immunopharma in a report on Tuesday, November 12th. Bank of America cut Lyell Immunopharma from a "buy" rating to an "underperform" rating and decreased their price objective for the stock from $6.00 to $1.00 in a research note on Wednesday, October 30th.

Lyell Immunopharma Stock Performance

Shares of NASDAQ:LYEL remained flat at $0.67 during mid-day trading on Monday. 1,795,318 shares of the company were exchanged, compared to its average volume of 1,039,921. The stock has a fifty day moving average of $1.05 and a 200 day moving average of $1.43. Lyell Immunopharma, Inc. has a 1-year low of $0.65 and a 1-year high of $3.26. The company has a market cap of $195.87 million, a price-to-earnings ratio of -0.85 and a beta of -0.45.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.03. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The company had revenue of $0.03 million for the quarter. On average, equities research analysts expect that Lyell Immunopharma, Inc. will post -0.8 EPS for the current fiscal year.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.